HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager patientINFORMation Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fox, L. A. Articles by Mauras, N. Search for Related Content PubMed PubMed Citation Articles by Fox, L. A. Articles by Mauras, N. Social Bookmarking                What's this?

A Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes

¹ Division of Endocrinology, Nemours Children’s Clinic, Jacksonville, Florida
² Division of Psychology and Psychiatry, Nemours Children’s Clinic, Jacksonville, Florida

Address correspondence and reprint requests to Larry A. Fox, MD, Nemours Children’s Clinic, NE Florida Pediatric Diabetes Center, 807 Children’s Way, Jacksonville, FL 32207. E-mail: lfox{at}lwpes.org

OBJECTIVE—This study assesses the effects of insulin pump therapy on diabetes control and family life in children 1–6 years old with type 1 diabetes.

RESEARCH DESIGN AND METHODS—Twenty-six children with type 1 diabetes for 6 months were randomly assigned to current therapy (two or three shots per day using NPH insulin and rapid-acting analog) or continuous subcutaneous insulin infusion (CSII) for 6 months. After 6 months, current therapy subjects were offered CSII. Changes in HbA_1c, mean blood glucose (MBG), hypoglycemia frequency, diabetes-related quality of life (QOL), and parental adjustment were recorded.

RESULTS—Eleven subjects from each group completed the trial (age 46.3 ± 3.2 months [means ± SE]). At baseline, there were no differences between groups in HbA_1c, MBG, age, sex, diabetes duration, or parental QOL. Mean HbA_1c, MBG, and parental QOL were similar between groups at 6 months. Mean HbA_1c and MBG did not change from baseline to 6 months in either group. The frequency of severe hypoglycemia, ketoacidosis, or hospitalization was similar between groups at any time period. Subjects on CSII had more fasting and predinner mild/moderate hypoglycemia at 1 and 6 months. Diabetes-related QOL improved in CSII fathers from baseline to 6 months. Psychological distress increased in current therapy mothers from baseline to 6 months. All subjects continued CSII after study completion.

CONCLUSIONS—CSII is safe and well tolerated in young children with diabetes and may have positive effects on QOL. CSII did not improve diabetes control when compared with injections, despite more mild/moderate hypoglycemia. The benefits and realistic expectations of CSII should be thoroughly examined before starting this therapy in very young children.

Abbreviations: CSII, continuous subcutaneous insulin infusion • MBG, mean blood glucose • QOL, quality of life

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Find additional patient-related information at:

Is Insulin Pump Therapy Better Than Insulin Injection Therapy for Toddlers With Type 1 Diabetes?

This article has been cited by other articles:

				S. Shalitin and M. Phillip Hypoglycemia in Type 1 Diabetes: A still unresolved problem in the era of insulin analogs and pump therapy Diabetes Care, February 1, 2008; 31(Supplement_2): S121 - S124. [Abstract] [Full Text] [PDF]

				D. Cody Infant and toddler diabetes Arch. Dis. Child., August 1, 2007; 92(8): 716 - 719. [Full Text] [PDF]

				M. Phillip, T. Battelino, H. Rodriguez, T. Danne, F. Kaufman, and for the Consensus forum participants Use of Insulin Pump Therapy in the Pediatric Age-Group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, June 1, 2007; 30(6): 1653 - 1662. [Full Text] [PDF]

				P.-M. Holterhus, R. Odendahl, S. Oesingmann, R. Lepler, V. Wagner, O. Hiort, R. Holl, and the German/Austrian DPV Initiative and the German Classification of Distinct Baseline Insulin Infusion Patterns in Children and Adolescents With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy Diabetes Care, March 1, 2007; 30(3): 568 - 573. [Abstract] [Full Text] [PDF]

				J. R. Wood, E. C. Moreland, L. K. Volkening, B. M. Svoren, D. A. Butler, and L. M.B. Laffel Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care, November 1, 2006; 29(11): 2355 - 2360. [Abstract] [Full Text] [PDF]

				E. A. Eugster, G. Francis, and and the Lawson-Wilkins Drug and Therapeutics Commi Position Statement: Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes Pediatrics, October 1, 2006; 118(4): e1244 - e1249. [Abstract] [Full Text] [PDF]

				A. T. Soliman, M. Omar, M. M. Rizk, A. El Awwa, and F. M. AlGhobashy Glycaemic Control with Modified Intensive Insulin Injections (MII) Using Insulin Pens and Premixed Insulin in Children with Type-1 Diabetes: A Randomized Controlled Trial J Trop Pediatr, August 1, 2006; 52(4): 276 - 281. [Abstract] [Full Text] [PDF]

				S. K. Varma Insulin Pump in Young Children with Diabetes AAP Grand Rounds, December 1, 2005; 14(6): 68 - 68. [Full Text] [PDF]